Olamkicept(sgp130Fc)阻断IL-6反式信号治疗活动性IBD的2a期试验
FUTURE是一项12周开放标签前瞻性2a期试验,16例活动性IBD患者接受IL-6反式信号抑制剂olamkicept治疗。药物耐受良好,临床应答率44%、临床缓解率19%;疗效伴随靶点抑制(pSTAT3降低)及黏膜转录改变,并鉴定出区别于抗TNF或抗整合素治疗的转录特征。提示阻断IL-6反式信号有望成为IBD新型免疫调节疗法。
要点
- olamkicept耐受良好,临床应答率44%、临床缓解率19%
- 疗效伴随pSTAT3降低及炎症黏膜转录改变
- 鉴定出区别于抗TNF/抗整合素的转录特征
核心结论
- 阻断IL-6反式信号在活动性IBD中显示良好前景,应开展完整临床开发作为新型免疫调节疗法。
研究设计与样本
- 12周开放标签前瞻性2a期试验(FUTURE),16例活动性IBD患者接受olamkicept治疗。
- 治疗诱导前后多时间点进行深度分子谱分析以明确作用机制。
主要发现
- olamkicept耐受良好,临床应答率44%、临床缓解率19%。
- 临床疗效与靶点抑制(磷酸化STAT3降低)及炎症黏膜显著转录改变一致。
- 鉴定出olamkicept特异性转录特征,可与英夫利西单抗或维得利珠单抗的缓解特征区分。
临床怎么用
- IL-6反式信号阻断可作为IBD新型免疫调节疗法的候选方向,需进一步完整临床开发。
局限性
- 开放标签、前瞻性2a期小样本试验(16例),无对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: A large unmet therapeutic need exists in inflammatory bowel disease (IBD). Inhibition of interleukin (IL)-6 appears to be effective, but the therapeutic benefit of a complete IL6/IL6 receptor (IL6R) blockade is limited by profound immunosuppression. Evidence has emerged that chronic proinflammatory activity of IL6 is mainly mediated by trans-signaling via a complex of IL6 bound to soluble IL6R engaging the gp130 co-receptor without the need for membrane-bound IL6R. We have developed a decoy protein, sgp130Fc, that exclusively blocks IL6 proinflammatory trans-signaling and has shown efficacy in preclinical models of IBD, without signs of immunosuppression. METHODS: We present a 12-week, open-label, prospective phase 2a trial (FUTURE) in 16 patients with active IBD treated with the trans-signaling inhibitor olamkicept (sgp130Fc) to assess the molecular mechanisms, safety, and effectiveness of IL6 trans-signaling blockade in vivo. We performed in-depth molecular profiling at various timepoints before and after therapy induction to identify the mechanism of action of olamkicept. RESULTS: Olamkicept was well tolerated and induced clinical response in 44% and clinical remission in 19% of patients. Clinical effectiveness coincided with target inhibition (reduction of phosphorylated STAT3) and marked transcriptional changes in the inflamed mucosa. An olamkicept-specific transcriptional signature, distinguishable from remission signatures of anti-tumor necrosis factor (infliximab) or anti-integrin (vedolizumab) therapies was identified. CONCLUSIONS: Our data suggest that blockade of IL6 trans-signaling holds great promise for the therapy of IBD and should undergo full clinical development as a new immunoregulatory therapy for IBD. (EudraCT no., Nu 2016-000205-36).
引用
- Schreiber S, Aden K, Bernardes JP, et al. Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in Patients With Active Inflammatory Bowel Disease. Gastroenterology. 2021. PMID: 33667488. doi:10.1053/j.gastro.2021.02.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。